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Abstract
Objective: This single-center, retrospective, observational cohort study evaluates the
appropriateness of the BioFire® FilmArray® Gastrointestinal (GI) multiplex PCR panel testing at
a community-teaching hospital.
Methods: All adult, hospitalized patients at Prisma Health Richland Hospital with a documented
GI multiplex PCR panel from 1 April 2015 through 28 February 2018 were included in the
analysis. Inappropriate use of the GI panel was defined as a test obtained without documented
diarrhea, greater than 2 days of hospitalization, redundant use with other diagnostic tests (e.g.
Clostridioides difficile PCR), or laxative use in the preceding 48 h. Antibiotic use and host variables
were compared between groups with positive and negative results.
Results: During the study period, 442 GI panels were obtained, among which 268 (61%) were
deemed inappropriate. Primary reasons for inappropriate testing were lack of documented
diarrhea (n = 92), greater than 2 days of hospitalization (n = 116), having a duplicate C. difficile
PCR test ordered (n = 118), or laxative use in the 48 h before testing (n = 36). A total of 141
(32%) GI panels were positive. The most frequently identified pathogens were C. difficile
(51.1%, n = 72), Enteropathogenic Escherichia coli (17.7%, n = 25), and Norovirus GI/GII (12.1%,
n = 17). Patients with negative GI panel results were initiated on antibiotics significantly less
frequently than those with positive GI panels (62.5% versus 80.2%, p < 0.00001).
Conclusion: Stewardship opportunities exist to optimize the diagnostic application of the GI
multiplex PCR panel.
Keywords: Clostridioides difficile, multiplex polymerase chain reaction, diagnostic stewardship,
antimicrobial stewardship, infectious diarrhea
Received: 3 July 2020; revised manuscript accepted: 27 August 2020.

Introduction
Since its development, application of polymerase
chain reaction (PCR) technology has transitioned
from genome projects and forensics to the expeditious and rapid identification of infectious diseases.1 The BioFire® FilmArray® Gastrointestinal
(GI) panel uses multiplex PCR technology for the
rapid detection of 22 pathogens causing infectious diarrhea.2 The pathogens recognized on this
panel are typically community-acquired, including several Escherichia coli pathotypes, additional
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bacteria, viruses, and gastrointestinal parasites.
Clostridioides difficile (toxin A/B) is also included
in the GI panel. Although historically considered
a nosocomial pathogen, community-acquired
cases of C. difficile infection (CDI) have surpassed
hospital and healthcare associated cases in South
Carolina,3 and represent roughly one-half of cases
nationally.4 With this comprehensive diagnostic
tool, results are available approximately 60 min
after sample processing in the laboratory, with a
reported 98.5% sensitivity and 99.2% specificity.2
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Use allows for earlier administration of appropriate anti-infective therapy, and has been shown to
reduce hospital length of stay and, importantly,
additional diagnostic testing.5
While the results of this panel directly influence
patient care, they also impact various benchmarks used to determine effectiveness of several
hospital departments. Antimicrobial stewardship
programs are assessed using metrics such as incidence rates of hospital-onset CDI, multi-drug
resistant bacteria, appropriateness of empiric and
definitive anti-infective therapy, and cost containment.6 These measurable outcomes are
important to determine the quality of stewardship initiatives. Similarly, in response to panel
results, a hospital’s infection control and prevention program will evaluate hospital-onset infections, and adherence to protocols including
contact precautions and appropriate hand
hygiene. With these rapid diagnostics housed in
the microbiology laboratory, the microbiology
department has jurisdiction over the execution of
the test and reporting of results. Thus, GI panel
results impact interdepartmental shared metrics,
making awareness and collaboration key to optimizing patient care.6

2

Methods
Study population
This study was conducted at Prisma Health
Richland, a 641-bed, community-teaching medical center (Columbia, SC, USA). All admitted
patients over the age of 18, who had the GI panel
conducted between 1 April 2015 and 28 February
2018 were included for analysis. Patients with
prolonged hospitalizations who had the GI panel
run more than once were entered as a new
encounter for each use of the test. Anyone under
the age of 18 or outpatients at the time of testing
were excluded.
The primary objective of this study was to determine appropriateness of GI panel testing. An
encounter was deemed “inappropriate” if it met
any of the following criteria: no reported or documented diarrhea, greater than 2 days of hospitalization prior to sample collection, concomitant or
post hoc singleplex Xpert® C. difficile PCR, or laxative use in preceding 48 h of sample collection.
Antibiotic use was compared between patients
with positive and negative GI panel results.

The concept of diagnostic stewardship is used
to offer organized guidelines for appropriate
use of these rapid diagnostics and improved
application to patient care. This includes guidance on identifying relevant patient populations
for testing, as well as education on the nuances
of newer technologies. A survey of stewardship
pharmacists’ familiarity with rapid diagnostic
technologies indicated multiplex PCR are the
most commonly utilized tests but least familiar
among respondents.7 This, along with the
increasing use of multiplex panels, leaves room
for significant educational intervention, and
highlights the need for diagnostic stewardship
to ensure optimal use of next generation rapid
diagnostics.

FilmArray GI panel
The GI panel tests for Campylobacter spp. (jejuni,
coli and upsaliensis), Clostridioides difficile (toxin
A/B), Plesiomonas shigelloides, Salmonella, Yersinia
enterocolitica, Vibrio spp. (parahaemolyticus, vulnificus and cholerae), Vibrio cholerae, Enteroaggregative
E. coli (EAEC), Enteropathogenic E. coli (EPEC),
Enterotoxigenic E. coli (ETEC) lt/st, Shiga-like
toxin-producing E. coli (STEC) stx1/stx2, E. coli
O157, Shigella/Enteroinvasive E. coli (EIEC),
Adenovirus F40/41, Astrovirus, Norovirus GI/
GII, Rotavirus A, Sapovirus (I, II, IV, and V),
Cryptosporidium,
Cyclospora
cayetanensis,
Entamoeba histolytica, and Giardia lamblia. The
assay was performed according to the manufacturer’s instructions and results were released to
the electronic health record (EHR).

This study evaluates appropriateness of the
BioFire® FilmArray® GI panel (referred to as GI
panel throughout) ordering at a large, community-teaching hospital to identify current demographic, temporal, and epidemiological trends
from descriptive data. These results will be used
to guide local recommendations for diagnostic
stewardship measures.

Data and statistics
Data were collected from the EHRs after de-identification and entered using REDCap®. Descriptive
statistics, frequency tables, and charts were used
to summarize the data using Microsoft Excel®
2007 (16.0.13029.20232). Quarterly increase in
use of test was assessed using a single-factor
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Figure 1. GI panel frequency of use. A total of 442 encounters occurred over the 35-month period.
GI panel, BioFire® Gastrointestinal panel.

Figure 2. Identified pathogens. There were 141 cases with positive test results, and the most commonly
identified pathogen was Clostridioides difficile Toxin A/B.

ANOVA. Antibiotic use and host factors were
compared between patients with positive and negative multiplex PCR results, respectively, using
chi-square test.
This study was approved as an exempt review by
the IRB of Prisma Health-Midlands (Pro00050721).
Due to the retrospective nature of this study, a
waiver of informed consent was granted.
Results
Among the GI panels screened during the study
period, 442 were included for assessment. There

journals.sagepub.com/home/tai

was a temporal increase in use of the GI panel over
time as demonstrated in Figure 1 (p < 0.00001).
Of the 442 uses, 141 yielded positive results
(31.9%). The most common pathogens identified
were C. difficile toxin A/B (72/141, 51.1%), EPEC
(25/141, 17.7%), and Norovirus GI/GII (17/141,
12.1%). Figure 2 shows the prevalence of all
pathogens identified in this study. In 20/141
(14.2%) cases, more than one pathogen was
detected, and the greatest number of pathogens
detected in a single sample was four (Vibrio spp.,
EAEC, EPEC, and Norovirus were all detected
in one panel).

3
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Table 1. Baseline characteristics.
Variable

Total (n = 442)

Age, years, mean (SD)

Positive test (n = 141)

Negative test (n = 301)

57 (18.1)

56 (18.6)

57.7 (17.9)

237 (53.6)

80 (56.7)

157 (52.2)

African American

232 (52.5)

62 (44.0)

170 (56.5)

Caucasian

192 (43.4)

71 (50.4)

121 (40.2)

Hispanic

8 (1.8)

3 (2.1)

5 (1.7)

Asian

3 (0.7)

2 (1.4)

1 (0.3)

Other

9 (2.0)

3 (2.1)

6 (2.0)

HIV positive, n (%)

35 (7.9)

13 (9.2)

22 (7.3)

Active cancer, n (%)

21 (4.8)

5 (3.5)

16 (5.3)

Chronic GI disorder, n (%)

81 (18.3)

22 (15.6)

59 (19.6)

311 (70.4)

111 (78.7)

200 (66.4)

36 (8.1)

12 (8.5)

24 (8.0)

Diabetes, n (%)

159 (36.0)

49 (34.8)

110 (36.5)

Recent hospitalization†, n (%)

157 (35.5)

43 (30.5)

114 (37.9)

12 (2.7)

3 (2.1)

9 (3.0)

184 (41.6)

53 (37.6)

131 (43.5)

30 (6.8)

10 (7.1)

20 (6.6)

Sex, male, n (%)
Race/Ethnicity n (%)

Acute diarrheax, n (%)♦
Liver cirrhosis, n (%)

Recent GI surgery*, n (%)
Prior antibiotic exposure†, n (%)
Use of immunosuppressants†, n (%)
†⩾48 h

duration within preceding 90 days.
preceding 30 days.
xExcludes chronic diarrhea (⩾28 days).
♦Indicates p ⩽ 0.05.
GI, gastrointestinal; HIV, human immunodeficiency virus; SD, standard deviation.
*Within

Pathogens on the panel that were not detected
during the study period included Vibrio cholerae,
Shiga-like toxin-producing E. coli, E. coli O157,
Cyclospora cayetanensis, and Entamoeba histolytica.
Baseline and clinical characteristics are outlined
in Tables 1 and 2, respectively. The mean age was
57 years and the majority of patients were male
(53.6%). The panel was run early in admission
for most patients, with 74.2% of tests being run
within the first 48 h of admission. Of the 442
records, 91 (20.6%) met qSOFA (quick sepsisrelated organ failure assessment) criteria for sepsis. There was a greater proportion of patients
with positive GI panels experiencing acute
4

diarrhea than those with negative results (78.7%
versus 66.4%, p < 0.00001). Recent hospitalization was higher in patients with negative panels
(37.9%) than in patients with positive panels
(30.5%), but the difference was not significant.
The proportion of patients who received tube
feeds was significantly higher in those with negative GI panels (1.4% versus 8.3% p < 0.00001).
Probiotic use was also significantly higher in this
population (2.1% versus 8.0%, p = 0.017). A total
of three patients had the panel run a second time,
and 118 (26.7%) had a concomitant separate
C. difficile PCR. Prior antibiotic exposure of at
least 48 h duration in the preceding 90 days was
confirmed in 184 cases (41.6%). Overall, the
journals.sagepub.com/home/tai
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Table 2. Clinical characteristics.
Variable

Total (n = 442)

Positive test (n = 141)

Negative test (n = 301)

Test conducted on hospital day ⩽ 2, n (%)

328 (74.2)

112 (79.4)

216 (71.8)

91 (20.6)

32 (22.7)

59 (19.6)

118 (26.7)

39 (27.7)

79 (26.2)

3 (0.7)

1 (0.7)

2 (0.7)

70 (15.8)

23 (16.3)

47 (15.6)

Separate stool culture, n (%)

153 (34.6)

56 (39.7)

97 (32.2)

Concurrent PEG tube, n (%)

16 (3.6)

3 (2.1)

13 (4.3)

Tube feeds‡, n (%)♦

27 (6.1)

2 (1.4)

25 (8.3)

Laxative use‡, n (%)

36 (8.1)

14 (9.9)

22 (7.3)

Stool softener use‡, n (%)

44 (10.0)

17 (12.1)

27 (9.0)

PPI use‡, n (%)

181 (41.0)

56 (39.7)

125 (41.5)

H2 use‡, n (%)

49 (11.1)

14 (9.9)

35 (11.6)

Probiotic use‡, n (%)♦

27 (6.1)

3 (2.1)

24 (8.0)

qSOFA ⩾2, n (%)
Concomitant or post hoc Clostridioides
difficile PCR, n (%)
Repeat GI panel, n (%)
Separate O&P, n (%)

‡Presumed

or documented use in preceding 48 h.
♦Indicates p ⩽ 0.05.
GI, gastrointestinal; qSOFA, quick sepsis-related organ failure assessment; O&P, ova and parasite; PCR, polymerase
chain reaction; PEG, percutaneous endoscopic gastrostomy; PPI, proton pump inhibitor; H2, H2 receptor antagonist; SD,
standard deviation.

most common agents with prior exposure were
vancomycin (38.3%), ceftriaxone (27.3%), and
metronidazole (24.6%).
Inappropriate use
There were a total of 268 records that met “inappropriate” use criteria, as displayed in Figure 3.
The most common reasons were tests conducted
after more than 2 days of hospitalization (n = 116),
and use of the C. difficile toxin B PCR in addition
to the GI panel (n = 118). Among the 118 records
that had both the GI panel and the C. difficile
PCR, 87 records (73.7%) had both tests run from
the same stool sample. The majority of inappropriate testing had a negative GI panel result
(188/268, 70.1%). Lack of reported or documented diarrhea was significantly higher in
patients with negative GI panels (p = 0.009); all
other criteria were not significantly different
between appropriate and inappropriate uses of
the test.
journals.sagepub.com/home/tai

There were 72 records with positive GI panels
indicating C. difficile toxin A/B. Concomitantly
identified pathogens included Campylobacter spp.
(n = 2),
Enteropathogenic
E. coli
(n = 5),
Cryptosporidium (n = 1), Norovirus GI/GII (n = 2),
and Sapovirus (n = 1). Of the 72 positive panels
for C. difficile, 18 also had an additional C. difficile
PCR test run. Of note, 15/18 (83.3%) had both
tests run on the same stool sample. In two cases,
the GI panel detected C. difficile, but the individual C. difficile PCR did not.
Among the 72 positive panels for C. difficile, 28
(38.9%) had a recent hospitalization, 34 (47.2%)
had confirmed or suspected use of a proton pump
inhibitor, and 31 (43.1%) had prior antibiotic
exposure. Median duration of reported diarrhea
was 2 days [interquartile range (IQR): 6.5 days].
The longest duration of diarrhea reported was
60 days. Mean white blood cell count was
11,400 cells/μl (±8160 cells/μl). The most common antibiotics used post-test were metronidazole
5
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Figure 3. Inappropriate use. A total of 268 encounters met at least one of the inappropriate use criteria.
Values reported are absolute numbers.
PCR, polymerase chain reaction.

Figure 4. Post-test antibiotic initiation by panel result. Antibiotics were not used post test in 19.8% of cases
with positive panel results versus 37.5% of cases with negative panel results.
GI panel, BioFire® Gastrointestinal panel.

(55/72, 76.4%), and/or oral vancomycin (39/72,
54.2%).
Impact on antibiotic therapy
Use of post-test antibiotics and duration of therapy were recorded (Figure 4). There were 28/141
(19.9%) patients with positive GI panels not initiated on antibiotics post test, compared with
113/301 (37.5%) in patients with negative GI
panels (p < 0.00001).

6

Mean days of therapy (DOT) for the first three
antibiotics used post test in all cases was 5.1 days;
those with positive panels had an average DOT of
5.4 days versus 4.8 days in those with negative
panels. Frequency of use for antibiotics used in
greater than 5% of patients, as well as average
duration is delineated for positive and negative
panels in Figures 5 and 6. The agents most frequently used in patients with positive GI panels
were metronidazole (48.9%), oral vancomycin
(27.7%), and ciprofloxacin (16.3%). The most

journals.sagepub.com/home/tai
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Figure 5. Breakdown of antibiotic use in positive panels. The most commonly used agents in this population
were metronidazole (48.9%), oral vancomycin (27.7%), and ciprofloxacin (16.3%).

Figure 6. Breakdown of antibiotic use in negative panels. The most commonly used agents in this population
were ceftriaxone (20.6%), metronidazole (19.3%), and intravenous vancomycin (16.3%).

common agents used in patients with negative GI
panels were ceftriaxone (20.6%), metronidazole
(19.3%), and intravenous vancomycin (16.3%).
Antibiotic therapy duration was also compared
between panels with either a negative or a viral
result (n = 288) and panels with a bacterial result
(n = 92). Altogether, these patients received an
average of 2.6 days and 5.0 days of antibiotics,
respectively (p < 0.001), and additional culture
positivity rates were not significantly different
between groups (37.3% versus 32.9%, p = 0.503).
In the cohort with negative or viral panel results,
114/288 (39.6%) did not receive antibiotic therapy, compared with 14/92 (15.2%) in the bacteria
journals.sagepub.com/home/tai

positive cohort (p < 0.0001). When excluding
those who did not receive antibiotics, average
days of therapy was 4.3 days for negative or viral
positive panels and 5.9 days for bacteria positive
panels.
Impact on other microbiological studies
Looking at traditional non-PCR technology, there
were 344 encounters with the GI panel that also
had culture data and 70 encounters that had an
ova and parasite (O&P) exam. The most common
culture site was blood (65.4%), followed by urine
(50%), stool (44.5%), and respiratory (14.8%).
Overall, additional cultures were positive in 40.4%
7
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Figure 7. Culture positivity by GI panel result. In 344 cases, a culture was taken in addition to the GI panel.
Overall, 40.4% of these additional cultures were positive.
GI panel, BioFire® Gastrointestinal panel.

of cases; Figure 7 displays culture positivity by GI
panel result. All O&P exams performed were
negative.
Discussion
In one of the largest reports of the BioFire
FilmArray® GI panel to date, we assessed 442
uses of the GI panel over a nearly 3-year period,
and found a 31.9% positivity rate, similar to previously reported data.5,8 The most commonly identified pathogen by the GI panel was C. difficile, a
leading cause of both community-acquired and
nosocomial infectious diarrhea.3,4,9 Investigators
determined “inappropriate use” criteria based on
factors considered wasteful (i.e., duplicate testing
with C. difficile PCR, performed after 48 h of hospitalization or no documented evidence of diarrhea) or confounding factors for interpretation of
results (e.g., laxative use). There were 118 records
that had duplicate C. difficile testing with the singleplex C. difficile PCR, a distinct opportunity for
diagnostic stewardship intervention. The majority
of redundant testing (73.7%) was done on the
same stool sample. Interdepartmental education
on appropriateness of testing is valuable, but many
institutions have leveraged the EHR to implement
a “soft” or “hard” stop, blocking duplicate ordering of these tests on an individual patient.10 In
addition, tests performed after 48 h of hospitalization which detect C. difficile may result in the CDI
labeled as hospital-acquired, despite a community-onset of infection, impacting infection control metrics and potentially reimbursement.11 The
GI multiplex panel has a 98.5% sensitivity to
8

C. difficile toxin A/B, making it difficult to distinguish between colonization and infection with
panel results alone.2 Of note, we determined a
1.7% discordance rate as there were two instances
where the GI panel detected C. difficile and the
Xpert® did not. This could be due to stool sample
quality or difference in gene detection by these
tests.12 There were no instances where the Xpert®
was positive and the GI panel was negative.
There are numerous reasons, both infections and
non-infectious, for acute or chronic diarrhea that
interfere with interpretation of results and appropriateness of testing. Laxative use in the preceding
48 h could potentially account for diarrhea or loose
stools. Laxative use was included in our inappropriate use definition and was common among all
patients (8%). Stool softener use was assessed
(10% among all patients) but not included in our
definition of inappropriate due to inconclusive evidence on effectiveness.13 Significant changes in
nutritional delivery, including enteral tube feeds,
prompted by gastrointestinal disease or surgery,
can be associated with both acute and sustained
diarrhea.14 Tube feed use was significantly more
common in patients with a negative GI PCR panel
(8.3% versus 1.4%) but was not included in the
definition of inappropriate test for this study. The
use of tube feeds and laxatives should be considered a criteria in the future for diagnostic stewardship of the GI panel as a potential non-infectious
cause of diarrhea. Similarly, diarrhea should be
present in the review of symptoms and documented before any tests should be conducted. As
mentioned previously, leveraging the EHR to
journals.sagepub.com/home/tai
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implement a “stop” to ordering the GI panel for
firm or solid stool samples should be considered.10
Among the 268 records that met “inappropriate”
use criteria, 43% (n = 116) were performed greater
than 2 days following initial hospitalization. Our
definition of inappropriate use included panels run
after more than 48 h of hospital admission due to
the low likelihood of these pathogens being community-acquired and the aforementioned concerns
with CDI. Baghdadi and colleagues showed diminished utility and lack of novel diagnoses when a
multiplex GI panel was run after more than 72 h of
hospitalization.15 Panels conducted well into hospital admission are not useful, and increase the risk
of incidental or collateral findings. Concerns with
hospital-acquired CDI should prompt testing with
a C. difficile-specific test. Negative GI panel results
were more common across all inappropriate use
criteria, significantly so in those without documented diarrhea (p = 0.009), so wasteful testing
could be mitigated through diagnostic stewardship
education and leveraging the EHR to guide clinicians to appropriate use of the GI PCR panel.
The utility of multiplex GI panels in antimicrobial
stewardship initiatives has been well studied.
These tests have recently been shown to reduce
time to appropriate antibiotic therapy and reduce
length of stay when compared with conventional
methods.16 They also provide a cost benefit via
reducing additional diagnostic stool tests and
imaging studies.5 Generally, the results of the GI
panel in this study produced an observable difference in antibiotic therapy as those with negative
panel results had reduced exposure to antibiotics.
Of the patients with negative GI panels, 113/301
(37.5%) did not receive antibiotics while inpatient,
and, in those that did receive antibiotic therapy,
the duration was numerically shorter (5.4 days versus 4.8 days). When looking at the positive GI
panel cohort, the high use of metronidazole and
oral vancomycin, aligns with the high proportion
of C. difficile toxin A/B identified in this group. As
expected, positive panel results aided in achieving
targeted antibiotic therapy. However, when looking at the 288 encounters where the panel did not
indicate antibiotics (negative or viral results) there
were 174 cases where at least one antibiotic was
given (60.4%). Of those cases, 144 had separate
cultures drawn, predominantly blood (74.5%) and
urine (57.9%). These cultures were positive in
67/144 (46.5%) instances, leaving 77/144 (53.5%)
to receive antibiotics potentially not indicated by
culture data or panel results. In the group where
journals.sagepub.com/home/tai

culture data indicated antibiotics and the GI panel
did not, 43/67 (64.2%) met inappropriate use criteria. In these patients, with more stringent screening, unnecessary use of multiplex GI panels could
be markedly reduced. Therefore, the best way to
optimize patient care is both further integration of
antibiotic stewardship for those who received antibiotics without indication, and implementing diagnostic stewardship measures for those where GI
panel results were less relevant to the nidus of
infection.
Many clinicians and staff across numerous departments are responsible for the ordering, conducting, and interpretation of these tests. The large
proportion of inappropriate tests in this study
indicate the need for enhanced diagnostic stewardship. Using electronic means, such as leveraging the EHR, appears to be effective in
implementing stewardship principles into diagnostics of acute diarrhea. These results will
prompt the implementation of both “soft” and
“hard” stop criteria into the EHR for the GI PCR
panel. Restrictions on timing of test ordering relative to hospital admission and repeat testing will
be included. Reducing redundancy in microbiologic tests will be a focus and included in the EHR
“hard” stops. Given the dynamic and advancing
landscape of rapid diagnostics, continued clinician education by stewardship teams will help
ensure appropriate interpretation and optimal
antimicrobial use based on testing results. All clinicians have a responsibility to be stewards of the
available diagnostics and antimicrobials to
improve cost effective patient care.
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